Research
Hormonal
There is good evidence for the efficacy and tolerability of approved anti-obesity pharmacotherapies in individuals with T2DM.
Clinicians should consider approved anti-obesity medications as part of treatment for patients with T2DM.
StrongSupportsmedium confidence
There is good evidence for the efficacy and tolerability of approved anti-obesity pharmacotherapies in individuals with T2DM.
Why this rating
The claim is based on a review of multiple pharmacotherapies.
Source
Pharmacotherapy for obesity in individuals with type 2 diabetes
Tariq Chukir et al. · Expert Opinion on Pharmacotherapy · 2018
DOI 10.1080/14656566.2018.1428558
reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →